"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to PRME. [ FAQ on what and how to ask] For non-PRME questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Allan Reine M.D.
Headquarter: 60 First Street, Cambridge, MA, United States, 02141
Industry: Biotechnology, Employees: 214
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
My Watchlist
